• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Thursday 07/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIPT

  • 11:31 AM

    In an Interview with CEOCFO Magazine, CEO Dr. Carl Schwartz Explains how the Company’s Database of Tumors, Artificial Intelligence Technology, and Groundbreaking Method for Growing Human Cancer Cells Makes it a Leader in Personalized Medicine EAGAN, MN / ACCESSWIRE / July 17, 2018 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (NASDAQ: AIPT). As Dr. Schwartz told CEOCFO’s Bud Wayne, Precision Therapeutics has become

    Read more
  • 4:39 PM

    MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office (“EPO”) granted European Patent No. 2948200  covering the Company’s STREAMWAY® System for automated, direct-to-drain medical fluid disposal, which is sold through the Company’s Skyline Medical division. The Company is seeking national validation of its European patent in 11 European countries, including

    Read more
  • 1:12 PM

    MINNEAPOLIS, June 28, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that it has signed a definitive merger agreement with Helomics Holding Corporation (“Helomics”). Upon completion of the merger, Precision will increase its equity stake in Helomics from 25% to 100%. This merger will provide Precision Therapeutics with full access to Helomics’ suite of Artificial Intelligence (AI), precision diagnostic and integrated CRO capabilities,

    Read more
  • 12:36 PM

    MINNEAPOLIS, May 31, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has launched a new website: www.precisiontherapeutics.com. This new site offers quick and easy access to essential information and features while offering a more comprehensive understanding of the Company’s value proposition and strategic direction in the precision medicine industry. It has a clean uncluttered design, improved functionality and enhanced content that better

    Read more
  • 12:29 PM

    Video News On PRECISION THERAPEUTICS, INC. – NASDAQ: AIPT   https://youtu.be/G7Vc44qfBMQ     About the STREAMWAY System Skyline’s revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency

    Read more
  • 5:08 PM

    MINNEAPOLIS, May 10, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery and producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announced today that it expects to secure its first European sales of the STREAMWAY® Systems in the second half of 2018. Based on the interest generated to date, and the stage of negotiations with several potential customers, the Company expects these

    Read more
Public Wire Banner